Skip to search formSkip to main contentSkip to account menu

Icrucumab

Known as: Anti-VEGFR-1 Monoclonal Antibody IMC-18F1, Anti-Vascular Endothelial Growth Factor Receptor-1 Monoclonal Antibody IMC-18F1 
A fully human IgG1 monoclonal antibody directed against human vascular endothelial growth factor receptor 1 (VEGFR-1/FLT-1) with potential… 
National Institutes of Health

Related topics

Related topics

4 relations
Antibody-Dependent Cellular CytotoxicityNCIt Antineoplastic Agent Terminologyantigen binding

Narrower (1)

IMC-18F1

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Імуногістохімічна характеристика експресії VEGF-A, VEGFR-1, VEGFR-2 і CD34 при прогресуванні колоректальної аденокарциноми
Aim – to study VEGF-A, VEGFR-1, VEGFR-2 and CD34 immunohistochemical expression on the I, II, III, IV stages (pTNM) of colorectal… 
2017
2017
Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.
BACKGROUND Icrucumab (ICR) and ramucirumab (RAM) bind vascular endothelial growth factor (VEGF) receptors 1 and 2 (VEGFR-1 and -2… 
Highly Cited
2016
Highly Cited
2016
Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled…
PURPOSE This trial assessed the efficacy and safety of docetaxel monotherapy or docetaxel in combination with ramucirumab… 
2016
2016
Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first…
BACKGROUND Icrucumab and ramucirumab are recombinant human IgG1 monoclonal antibodies that bind VEGF receptors 1 and 2 (VEGFR-1… 
2015
2015
Interim results of a randomized phase 2 study of docetaxel with ramucirumab versus docetaxel in second-line advanced or metastatic urothelial carcinoma.
295 Background: Patients (pts) with metastatic urothelial carcinoma (UC) progressing after first-line chemotherapy have limited… 
2014
2014
Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study
SummaryBackground IMC-18F1 (icrucumab), a human monoclonal antibody against vascular endothelial growth factor receptor-1 (VEGFR… 
2013
2013
Avaliação dos fatores de crescimento endotelial vascular VEGF e de seus principais receptores VEGFR-1 e -2 no processo de cicatrização com influência da radioterapia em ratos da linhagem Wistar
2012
2012
Randomized phase II study of docetaxel with or without ramucirumab (IMC-1121B) or icrucumab (IMC-18F1) in patients with urothelial transitional cell carcinoma (TCC) following progression on first…
TPS4675^ Background: The vascular endothelial growth factor (VEGF) pathway may play an important role in the pathogenesis of… 
2007
2007
Epithelial expression of VEGF receptors in colorectal carcinomas and their relationship to metastatic status.
BACKGROUND Vascular endothelial growth factor (VEGF), originally identified as an endothelium-specific factor, can also bind to… 
2005
2005
Vascular endothelial growth factor activities on osteoarthritic chondrocytes.
OBJECTIVE Evaluation of the role of VEGF in cartilage pathophysiology. METHODS VEGF release from chondrocytes in the presence… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)